Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure

Minerva Cardioangiologica

Volumn 51, Issue 2, 2003, Pages 155-164

  Bauersachs, J ^a   Fraccarollo, D ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Angiotensin converting enzyme inhibitors; Diuretics; Heart failure, congestive, drug therapy; Renin angiotensin system

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; POTASSIUM; SODIUM; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; EXERCISE; EXTRACELLULAR MATRIX; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FUNCTION; MAXIMUM PERMISSIBLE DOSE; PATHOPHYSIOLOGY; POTASSIUM BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM EXCRETION; SODIUM URINE LEVEL;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; SPIRONOLACTONE;

EID: 0038351745     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-7.
2. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.
3. Delcayre C, Silvestre JS. Aldosterone and the heart: towards a physiological function? Cardiovasc Res 1999;43:7-12.
4. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992;71:503-10.
5. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 β-hydroxysteroid dehydrogenase in the human heart. Circulation 1995;92:175-82.
6. Christ M, Wehling M. Cardiovascular steroid actions: swift swallows or sluggish snails? Cardiovasc Res 1998; 40:34-44.
7. Silvestre JS, Robert V, Aupetit-Faisant B, Heymes C, Mouas C, Moalic JM et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998;273:4883-91.
8. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694-701.
9. Christ M, Kellner M, Wehling M, Lombes M, Fraccarollo D, Ertl G et al. Modulation of cardiac aldosterone synthase and type I mineralocorticoid receptor expression in experimental chronic heart failure. Eur Heart J 2000;21Suppl:251.
10. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Cardiac aldosterone production in genetically hypertensive rats. Hypertension 2000;36:495-500.
11. Yamamoto N, Yasue H, Mizuno Y, Yoshimura M, Fujii H, Nakayama M et al. Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension 2002;39:958-62.
12. Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103:72-7.
13. Yoshimura M, Nakamura S, Ito T, Nakayama M, Harada E, Mizuno Y et al. Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 2002;87:3936-40.
14. Mizuno Y, Yasue H, Yoshimura M, Fujii H, Yamamoto N, Nakayama M et al. Effects of perindopril on aldosterone production in the failing human heart. Am J Cardiol 2002;89:1197-200.
15. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25:563-75.
16. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999;33:981-6.
17. Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001;104:137-9.
18. Lacolley P, Safar ME, Lucet B, Ledudal K, Labat C, Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001;37:662-7.
19. Rossi GP, Di BV, Ganzaroli C, Sacchetto A, Cesari M, Bertini A et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002;40:23-7.
20. Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-κb activation in angiotensin II-induced cardiac injury. Hypertension 2001; 37(Part 2):787-93.
21. Takeda Y, Yoneda T, Demura M, Usukura M, Mabuchi H. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation 2002;105: 677-9.
22. Rossi GP, Sacchetto A, Cesari M, Pessina AC. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 1999;43:300-7.
23. Oshima Y, Fujio Y, Funamato M, Negoro S, Izumi M, Nakaoka Y et al. Aldosterone augments endothelin-1-induced cardiac myocyte hypertrophy with the reinforcement of the JNK pathway. FEBS Lett 2002;542:123-6.
24. Duprez DA, Bauwens FR, De Buyzere ML, De Backer TL, Kaufman JM, Van Hoecke J et al. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1993;71:17A-20.
25. Kupari M, Hautanen A, Lankinen L, Koskinen P, Virolainen J, Nikkila H et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998;97:569-75.
26. Schunkert H, Hengstenberg C, Holmer SR, Broeckel U, Luchner A, Muscholl MW et al. Lack of association between a polymorphism of the aldosterone synthase gene and left ventricular structure. Circulation 1999;99: 2255-60.
27. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2001;38:1375-82.
28. Hengstenberg C, Holmer SR, Mayer B, Lowel H, Engel S, Hense HW et al. Evaluation of the aldosterone synthase (CYP11B2) gene polymorphism in patients with myocardial infarction. Hypertension 2000;35:704-9.
29. Tiago AD, Badenhorst D, Skudicky D, Woodiwiss AJ, Candy GP, Brooksbank R et al. An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy. Cardiovasc Res 2002;54:584-9.
30. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
31. Smith AG. Spironolactone in the long-term management of patients with congestive heart failure. Curr Med Res Opin 1980;7:131-6.
32. Cohn JN. The management of chronic heart failure. N Engl J Med 1996;335:490-8.
33. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Consensus Trial Study Group. Circulation 1990;82:1730-6.
34. Staessen J, Lijnen P, Fagard R, Verschuren L, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;91:457-65.
35. Sato A, Suzuki Y, Shibata H, Saruta T. Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients. Hypertens Res 2000;23:25-31.
36. Farquharson CA, Struthers AD. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol 2002;39:767-75.
37. Jorde UP, Ennezat PV, Lisker J, Suryadevara V, Infeld J, Cukon S et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000;101: 844-6.
38. Jorde UP, Vittorio T, Katz SD, Colombo PC, Latif F, Le Jemtel TH. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 2002;106:1055-7.
39. Tang WH, Vagelos RH, Yee YG, Benedict CR, Willson K, Liss CL et al. Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002;39:70-8.
40. Cicoira M, Zanolla L, Franceschini L, Rossi A, Golia G, Zeni P et al. Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2002;89:403-7.
41. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Cabrini G et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001;37: 1808-12.
42. Bauersachs J, Fraccarollo D, Ertl G, Gretz N, Wehling M, Christ M. Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE-inhibition: mechanistic evidence to support RALES. Circulation 2000;102:2325-8.
43. Bauersachs J, Heck M, Fraccarollo D, Hildemann S, Ertl G, Wehling M et al. Addition of spironolactone to ACE inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial NO synthase expression. J Am Coll Cardiol 2002;39:351-8.
44. Barbato JC, Mulrow PJ, Shapiro JI, Franco-Saenz R. Rapid effects of aldosterone and spironolactone in the isolated working rat heart. Hypertension 2002;40: 130-5.
45. Sato A, Suzuki Y, Saruta T. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999;22:17-22.
46. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102:2700-6.
47. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001;37:1228-33.
48. Modena MG, Aveta P, Menozzi A, Rossi R. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001;141:41-6.
49. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2002;40:304-10.
50. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7.
51. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 2002;38:1107-11.
52. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002;40:504-10.
53. Beck L, Blanc-Guillemaud V, Cherif OK, Jover B, Davy JM. Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. Cardiology 2001;96: 85-93.
54. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-4.
55. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-65.
56. Jolobe OM. Efficacy of low-dose captopril in addition to furosemide and spironolactone in patients with decompensated liver disease during blunted diuresis. J Hepatol 1993;19:321-2.
57. McLay JS, McMurray JJV, Bridges AB, Fraser JD, Struthers AD. Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure. Am Heart J 1993;126:879-86.
58. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2000;110:438-41.
59. Blaustein DA, Babu K, Reddy A, Schwenk MH, Avram MM. Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade. Am J Cardiol 2002;90:662-3.
60. Obialo CI, Ofili EO, Mirza T. Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol 2002;90: 663-5.
61. Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000;57:1408-11.
62. Delyani JA, Rocha R, Cook CS, Tobert DS, Levin S, Roniker B et al. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev 2001; 19:185-200.
63. Krum H, Nolly H, Workman D, He W, Roniker B, Krause S et al. Efficacy of eplerenone added to reninangiotensin blockade in hypertensive patients. Hypertension 2002;40:117-23.
64. Quaschning T, Ruschitzka F, Shaw S, Luscher TF. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 2001;37(2 Part 2):801-5.
65. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002;105:2212-6.
66. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001;104:467-72.
67. Martinez DV, Rocha R, Matsumura M, Oestreicher E, Ochoa-Maya M, Roubsanthisuk W et al. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 2002;39(2 Pt 2):614-8.
68. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001;281: H647-54.
69. Sabbah HN, Suzuki G, Morita H, Sharov VG, Todor A, Goldstein S. Eplerenone, a novel aldosterone receptor antagonist, prevents progressive left ventricular dysfunction and remodelling in dogs with heart failure. Eur Heart J 2002;23Suppl:370.
70. Bauersachs J, Fraccarollo D, Schäfer A, Hildemann S, Galuppo P, Ertl G. Improvement of ventricular remodeling in rats with CHF: comparative and combined effects of aldosterone receptor blockade and angiotensin converting enzyme inhibition. Eur Heart J 2002;23Suppl:401.
71. Schäfer A, Fraccarollo D, Hildemann S, Christ M, Eigenthaler M, Kobsar A et al. Inhibition of platelet activation in congestive heart failure by selective aldsterone receptor antagonism and angiotensin converting enzyme inhibition. Eur Heart J 2002;23Suppl:401.
72. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F et al. The Ephesus trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79-87.